drug
(ledipasvir + sofosbuvir)
Marketedupdated 3mo agoby $GILD GILEAD SCIENCES, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (ledipasvir + sofosbuvir)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 28, 2026
8 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (128)
- Jul 30, 2034patentUS 10039779*PED
- Jul 30, 2034patentUS 10039779*PED
- Jan 30, 2034compositionUS 10039779
- Jan 30, 2034compositionUS 10039779
- Mar 14, 2033patentUS 9393256*PED
- Mar 14, 2033patentUS 9393256*PED
- Mar 14, 2033patentUS 9393256*PED
- Mar 14, 2033patentUS 9393256*PED
- Sep 14, 2032formulationUS 10456414
- Sep 14, 2032formulationUS 10456414
- Sep 14, 2032formulationUS 10456414
- Sep 14, 2032formulationUS 10456414
- Sep 14, 2032method-of-use (U-1470)US 9393256
- Sep 14, 2032method-of-use (U-1470)US 9393256
- Sep 14, 2032method-of-use (U-1470)US 9393256
- Sep 14, 2032method-of-use (U-1470)US 9393256
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Nov 12, 2030patentUS 8088368*PED4.2y
- Nov 12, 2030patentUS 8088368*PED4.2y
- Nov 12, 2030patentUS 8088368*PED4.2y
- Nov 12, 2030patentUS 8088368*PED4.2y
- Nov 12, 2030patentUS 8273341*PED4.2y
- Nov 12, 2030patentUS 8273341*PED4.2y
- Nov 12, 2030patentUS 8273341*PED4.2y
- Nov 12, 2030patentUS 8273341*PED4.2y
- Nov 12, 2030patentUS 8822430*PED4.2y
- Nov 12, 2030patentUS 8822430*PED4.2y
- Nov 12, 2030patentUS 8822430*PED4.2y
- Nov 12, 2030patentUS 8822430*PED4.2y
- Nov 12, 2030patentUS 8841278*PED4.2y
- Nov 12, 2030patentUS 8841278*PED4.2y
- Nov 12, 2030patentUS 8841278*PED4.2y
- Nov 12, 2030patentUS 8841278*PED4.2y
- Nov 12, 2030patentUS 9511056*PED4.2y
- Nov 12, 2030patentUS 9511056*PED4.2y
- Nov 12, 2030patentUS 9511056*PED4.2y
- Nov 12, 2030patentUS 9511056*PED4.2y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- May 12, 2030compositionUS 80883683.7y
- May 12, 2030compositionUS 80883683.7y
- May 12, 2030compositionUS 80883683.7y
- May 12, 2030compositionUS 80883683.7y
- May 12, 2030method-of-use (U-1470)US 82733413.7y
- May 12, 2030method-of-use (U-1470)US 82733413.7y
- May 12, 2030method-of-use (U-1470)US 82733413.7y
- May 12, 2030method-of-use (U-1470)US 82733413.7y
- May 12, 2030compositionUS 88224303.7y
- May 12, 2030compositionUS 88224303.7y
- May 12, 2030compositionUS 88224303.7y
- May 12, 2030compositionUS 88224303.7y
- May 12, 2030formulationUS 88412783.7y
- May 12, 2030formulationUS 88412783.7y
- May 12, 2030formulationUS 88412783.7y
- May 12, 2030formulationUS 88412783.7y
- May 12, 2030method-of-use (U-1470)US 95110563.7y
- May 12, 2030formulationUS 95110563.7y
- May 12, 2030method-of-use (U-1470)US 95110563.7y
- May 12, 2030method-of-use (U-1470)US 95110563.7y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8735372*PED2.1y
- Sep 21, 2028patentUS 8735372*PED2.1y
- Sep 21, 2028patentUS 8735372*PED2.1y
- Sep 21, 2028patentUS 8735372*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028method-of-use (U-1470)US 87353721.6y
- Mar 21, 2028method-of-use (U-1470)US 87353721.6y
- Mar 21, 2028method-of-use (U-1470)US 87353721.6y
- Mar 21, 2028method-of-use (U-1470)US 87353721.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
FDA exclusivities (8)
- Aug 28, 2026ODE*ODE*8d
- Aug 28, 2026ODE*ODE*8d
- Aug 28, 2026ODE-262Orphan Drug (7y)8d
- Aug 28, 2026ODE-263Orphan Drug (7y)8d
- Aug 28, 2026ODE-264Orphan Drug (7y)8d
- Aug 28, 2026ODE-262Orphan Drug (7y)8d
- Aug 28, 2026ODE-263Orphan Drug (7y)8d
- Aug 28, 2026ODE-264Orphan Drug (7y)8d
News(1)
- Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialAtea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment regimen.fiercebiotech · 22d ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that